ReviewCancer journal (Sudbury, Mass.)
Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer.
Review in Cancer journal (Sudbury, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Associations between vascular endothelial growth factor polymorphisms and prostate cancer risk: a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer.Clinical genitourinary cancer · 2015Trial
- Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib.JAMA dermatology · 2015Trial
- Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer.Investigational new drugs · 2024Article
- Computational drug discovery for castration-resistant prostate cancers through in vitro drug response modeling.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Choosing Kinase Inhibitors for Androgen Deprivation Therapy-Resistant Prostate Cancer.Pharmaceutics · 2022Review
- A Tailored Approach for Appendicular Impending and Pathologic Fractures in Solid Cancer Metastases.Cancers · 2022Review
- Combination of AZD3463 and DZNep Prevents Bone Metastasis of Breast Cancer by Suppressing Akt Signaling.Frontiers in pharmacology · 2021Article
- Immuno-PET imaging of VEGFR-2 expression in prostate cancer withAmerican journal of cancer research · 2019Article
- Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience.Therapeutic advances in urology · 2016Review
- Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'?Targeted oncology · 2016Review
- Curcumin mediates reversion of HGF-induced epithelial-mesenchymal transition via inhibition of c-Met expression in DU145 cells.Oncology letters · 2016Article
- Article
- Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer.Oncotarget · 2015Review
- Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy.Oncotarget · 2015Article
- The systemic delivery of an oncolytic adenovirus expressing decorin inhibits bone metastasis in a mouse model of human prostate cancer.Gene therapy · 2015Article
- Integrating new discoveries into the "vicious cycle" paradigm of prostate to bone metastases.Cancer metastasis reviews · 2014Review
- In reply.The oncologist · 2014Article
- Cabozantinib and prostate cancer: inhibiting seed and disrupting soil?Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy.Journal of nanomedicine & nanotechnology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Effective management of bone metastases in men with castration-resistant prostate cancer (CRPC) remains an important unmet medical need. MET and vascular endothelial growth factor receptor (VEGFR) are rational targets for intervention in CRPC. Clinical trials involving agents that inhibit one but not both pathways have reported modest activity and no improvement in overall survival. Cabozantinib is an oral multitargeted tyrosine kinase inhibitor that inhibits both MET and VEGFR-2. A phase II randomized discontinuation study involving subjects with CRPC demonstrated that cabozantinib therapy is associated with improvement in bone scans, bone turnover markers, and pain response, but with significant adverse events leading to dose reduction and treatment discontinuation. Lower doses of cabozantinib retain high levels of activity with less toxicity. Ongoing phase III clinical trials will define the role of cabozantinib in CRPC. We summarize the rationale for targeting MET and VEGFR pathways in CRPC and the clinical data available to date.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.